Atai & Beckley Psychedelic Merger Creates Global Mental Health Leader
Atai Life Sciences and Beckley Psytech are merging in an all-stock transaction, creating atai Beckley, a leading mental health...
Editor's Choice
Promising Data: Alrizomadlin in Solid Tumors
Ascentage Pharma released Phase II clinical trial data for its MDM2-p53 inhibitor, alrizomadlin (APG-115), at the 2025 ASCO Annual...
RECELL Reduced Hospital Stays: Largest Real-World Analysis
AVITA Medical highlighted data from the British Burn Association Annual Meeting showing that RECELL, its spray-on skin cell technology,...
Polypid’s Shield II Phase 3 Trial Delivers Groundbreaking Results
PolyPid Ltd. announced positive topline results from its Phase 3 SHIELD II trial of D-PLEX100 for preventing surgical site...
Humacyte’s AV Access Study Shows Promising Results
Humacyte, a biotech company focused on bioengineered human tissues, presented positive Phase 3 clinical trial results for their acellular...
Metsera Announces Positive Phase 1 Data of Amylin Candidate
Metsera, Inc. announced positive Phase 1 clinical trial data for MET-233i, a new ultra-long-acting amylin analog designed for monthly...
Lisaftoclax Data in Venetoclax-Refractory Patients from ASCO 2025
Ascentage Pharma presented Phase Ib/II data at the 2025 ASCO Annual Meeting for lisaftoclax, a Bcl-2 inhibitor, combined with...
Ziftomenib Monotherapy Shows Positive Pivotal Data at ASCO 2025
Kura Oncology and Kyowa Kirin announced positive Phase 2 trial results for ziftomenib, an oral menin inhibitor, in patients...
Onvansertib and Paclitaxel Show Promising Results in Metastatic TNBC
Cardiff Oncology announced positive data from a Phase 1b clinical trial of onvansertib combined with paclitaxel for metastatic triple-negative...
4D Path Biomarker Predicts Breast Cancer Treatment Response
4D Path presented groundbreaking findings at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting, demonstrating that their...
